Complete response to bicalutamide withdrawal prolonged for almost 2 years in patients with metastatic prostate cancer

Hiroshi Hongo, Takeo Kosaka, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)


This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2years in a patient with metastatic prostate cancer. An 80-year-old man who had prostate-specific antigen (PSA) level elevation (168.1ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1ng/mL but started increasing again and reached 1.64ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2years.

Original languageEnglish
Pages (from-to)150-151
Number of pages2
JournalUrology Case Reports
Issue number5
Publication statusPublished - 2014 Sep



  • Antiandrogen withdrawal syndrome
  • Bicalutamide
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this